semaglutide not working for me Who should take semaglutide? How Semaglutide Transformed My Weight

This study was approved by the Inonu University Health Sciences Non-Interventional Clinical Research Ethics Committee (approval number: 2024/6557)

Cardiovascular Risk Indication In 2024, semaglutide 2.4 mg (Wegovy) received an additional FDA indication: reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

Disclosure statement Craig Russell does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment

Neither retatrutide nor cagrilintide is currently FDA-approved

Though human studies are still in the early stages, initial findings are promising, suggesting benefits in metabolism and physical endurance without major side effects

How the Medications Work Simple, Effective and Proven Results Our compounded semaglutide and compounded tirzepatide injections are a natural, weekly therapy enhanced with essential vitamins for optimal weight loss